Compare Biocon Ltd with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs AUROBINDO PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON AUROBINDO PHARMA BIOCON /
AUROBINDO PHARMA
 
P/E (TTM) x 18.5 10.1 183.3% View Chart
P/BV x 2.9 2.2 130.6% View Chart
Dividend Yield % 0.4 0.6 70.8%  

Financials

 BIOCON    AUROBINDO PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-18
AUROBINDO PHARMA
Mar-18
BIOCON /
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,188809 146.8%   
Low Rs305504 60.5%   
Sales per share (Unadj.) Rs68.7281.1 24.5%  
Earnings per share (Unadj.) Rs7.641.4 18.3%  
Cash flow per share (Unadj.) Rs14.050.9 27.5%  
Dividends per share (Unadj.) Rs1.002.50 40.0%  
Dividend yield (eoy) %0.10.4 35.2%  
Book value per share (Unadj.) Rs86.3199.4 43.3%  
Shares outstanding (eoy) m600.00585.88 102.4%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.92.3 465.0%   
Avg P/E ratio x98.915.9 622.7%  
P/CF ratio (eoy) x53.412.9 414.1%  
Price / Book Value ratio x8.63.3 262.5%  
Dividend payout %13.26.0 219.1%   
Avg Mkt Cap Rs m447,900384,630 116.4%   
No. of employees `0006.117.3 35.5%   
Total wages/salary Rs m9,31121,308 43.7%   
Avg. sales/employee Rs Th6,705.89,500.7 70.6%   
Avg. wages/employee Rs Th1,514.21,229.4 123.2%   
Avg. net profit/employee Rs Th736.91,397.9 52.7%   
INCOME DATA
Net Sales Rs m41,234164,666 25.0%  
Other income Rs m2,0621,020 202.2%   
Total revenues Rs m43,296165,686 26.1%   
Gross profit Rs m8,29137,718 22.0%  
Depreciation Rs m3,8515,580 69.0%   
Interest Rs m615777 79.1%   
Profit before tax Rs m5,88732,380 18.2%   
Minority Interest Rs m21331 678.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5698,183 19.2%   
Profit after tax Rs m4,53124,229 18.7%  
Gross profit margin %20.122.9 87.8%  
Effective tax rate %26.725.3 105.5%   
Net profit margin %11.014.7 74.7%  
BALANCE SHEET DATA
Current assets Rs m41,486121,878 34.0%   
Current liabilities Rs m21,41386,806 24.7%   
Net working cap to sales %48.721.3 228.6%  
Current ratio x1.91.4 138.0%  
Inventory Days Days64130 49.2%  
Debtors Days Days9468 137.7%  
Net fixed assets Rs m50,66181,037 62.5%   
Share capital Rs m3,000586 512.0%   
"Free" reserves Rs m48,808116,218 42.0%   
Net worth Rs m51,808116,804 44.4%   
Long term debt Rs m17,8984,512 396.7%   
Total assets Rs m99,897211,052 47.3%  
Interest coverage x10.642.7 24.8%   
Debt to equity ratio x0.30 894.3%  
Sales to assets ratio x0.40.8 52.9%   
Return on assets %5.211.8 43.5%  
Return on equity %8.720.7 42.2%  
Return on capital %9.627.4 35.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05880,727 14.9%   
Fx outflow Rs m7,34834,700 21.2%   
Net fx Rs m4,71046,027 10.2%   
CASH FLOW
From Operations Rs m6,62119,548 33.9%  
From Investments Rs m-6,840-19,570 35.0%  
From Financial Activity Rs m-2,3978,642 -27.7%  
Net Cashflow Rs m-2,6128,922 -29.3%  

Share Holding

Indian Promoters % 40.4 54.1 74.7%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 8.0 105.7%  
FIIs % 10.7 27.7 38.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.2 195.1%  
Shareholders   109,995 69,601 158.0%  
Pledged promoter(s) holding % 0.0 8.6 0.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  TTK HEALTHCARE  PROCTER & GAMBLE HEALTH  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

DHFL Saga, Falling Passenger Vehicle Sales, and Top Cues in Focus Today(Pre-Open)

Indian share markets witnessed buying interest on Friday and ended their volatile trading session on a positive note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Oct 11, 2019 (Close)

TRACK BIOCON

BIOCON - SUVEN LIFESCIENCES COMPARISON

COMPARE BIOCON WITH

MARKET STATS